v3.26.1
Note 13 - Net Loss per Share
 3 Months Ended
Mar. 31, 2026
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 13 — Net Loss Per Share

 

The Net loss per share basic and diluted for the respective periods indicated is as follows:

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2026

 

 

2025

 

Numerator

 

 

 

 

 

 

 

 

Net loss

 

$

(13,909

)

 

$

(26,908

)

Series B Convertible Preferred Stock dividends earned

 

 

(9,719

)

 

 

(9,110

)

Net loss attributable to Lucid Diagnostics Inc. common stockholders

 

$

(23,628

)

 

$

(36,018

)

 

 

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

140,096,782

 

 

 

68,796,392

 

 

 

 

 

 

 

 

 

 

Net loss per share (1)

 

 

 

 

 

 

 

 

Net loss per share - basic and diluted

 

$

(0.17

)

 

$

(0.52

)

 

(1)

- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

 

Basic weighted-average number of shares of common stock outstanding for the three months ended March 31, 2026 and 2025 includes the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares of common stock outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

 

 

 

March 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

Stock options

 

 

12,353,542

 

 

 

9,956,444

 

Unvested restricted stock awards

 

 

12,295,240

 

 

 

6,584,240

 

Shares held in abeyance

 

 

13,294,267

 

 

 

—

 

Preferred stock

 

 

16,823,764

 

 

 

49,607,115

 

Total

 

 

54,766,813

 

 

 

66,147,799